Erez Dror
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Erez Dror has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Marianne Böni-Schnetzler
Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland
6 shared publications Constanze Thienel
Clinic of Endocrinology, Diabetes and Metabolism University Hospital Basel, Basel, Switzerland, and Department of Biomedicine, University of Basel, Basel, Switzerland
4 shared publicationsShuyang Traub
Clinic of Endocrinology, Diabetes and Metabolism University Hospital Basel and Department Biomedicine, University of Basel, 4031, Basel, Switzerland
4 shared publications- Elise Dalmas
Institut Necker Enfants Malades (INEM), INSERM U1151–CNRS UMRS 8253, IMMEDIAB Laboratory, Université Paris Cité, 75015 Paris, France
3 shared publications - François Pattou
Inserm, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1190-European Genomic Institute for Diabetes, Université de Lille
3 shared publications Friederike Schulze
Clinic of Endocrinology, Diabetes and Metabolism University Hospital Basel and Department Biomedicine, University of Basel, 4031, Basel, Switzerland
3 shared publications
Latest Publications
- Open Access
- 24 July 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-10
The Role of Inflammation in β-cell Dedifferentiation
Chronic inflammation impairs insulin secretion and sensitivity. β-cell dedifferentiation has recently been proposed as a mechanism underlying β-cell failure in T2D. Yet the effect of inflammation on β-cell identity in T2D has not been studied. Therefore, we investigated whether pro-inflammatory cytokines induce β-cell dedifferentiation and whether anti-inflammatory treatments improve insulin secretion via β-cell redifferentiation. We observed that IL-1β, IL-6 and TNFα promote β-cell dedifferentiation in cultured human and mouse islets, with IL-1β being the most potent one of them. In particular, β-cell identity maintaining transcription factor Foxo1 was downregulated upon IL-1β exposure. In vivo, anti-IL-1β, anti-TNFα or NF-kB inhibiting sodium salicylate treatment improved insulin secretion of isolated islets. However, only TNFα antagonism partially prevented the loss of β-cell identity gene expression. Finally, the combination of IL-1β and TNFα antagonism improved insulin secretion of ex vivo isolated islets in a synergistic manner. Thus, while inflammation triggered β-cell dedifferentiation and dysfunction in vitro, this mechanism seems to be only partly responsible for the observed in vivo improvements in insulin secretion.
- 24 July 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-10
Open AccessThe Role of Inflammation in β-cell Dedifferentiation
Chronic inflammation impairs insulin secretion and sensitivity. β-cell dedifferentiation has recently been proposed as a mechanism underlying β-cell failure in T2D. Yet the effect of inflammation on β-cell identity in T2D has not been studied. Therefore, we investigated whether pro-inflammatory cytokines induce β-cell dedifferentiation and whether anti-inflammatory treatments improve insulin secretion via β-cell redifferentiation. We observed that IL-1β, IL-6 and TNFα promote β-cell dedifferentiation in cultured human and mouse islets, with IL-1β being the most potent one of them. In particular, β-cell identity maintaining transcription factor Foxo1 was downregulated upon IL-1β exposure. In vivo, anti-IL-1β, anti-TNFα or NF-kB inhibiting sodium salicylate treatment improved insulin secretion of isolated islets. However, only TNFα antagonism partially prevented the loss of β-cell identity gene expression. Finally, the combination of IL-1β and TNFα antagonism improved insulin secretion of ex vivo isolated islets in a synergistic manner. Thus, while inflammation triggered β-cell dedifferentiation and dysfunction in vitro, this mechanism seems to be only partly responsible for the observed in vivo improvements in insulin secretion.
- Open Access
- 1 March 2017
- Published by Elsevier in Cell Reports
- Vol. 18 (13) , 3192-3203
Pancreatic α Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis
- 1 March 2017
- Published by Elsevier in Cell Reports
- Vol. 18 (13) , 3192-3203
Open AccessPancreatic α Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis
- Top Cited Papers
- 16 January 2017
- Published by Springer Nature in Nature Immunology
- Vol. 18 (3) , 283-292
Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation
The deleterious effect of chronic activation of the IL-1β system on type 2 diabetes and other metabolic diseases is well documented. However, a possible physiological role for IL-1β in glucose metabolism has remained unexplored. Here we found that feeding induced a physiological increase in the number of peritoneal macrophages that secreted IL-1β, in a glucose-dependent manner. Subsequently, IL-1β contributed to the postprandial stimulation of insulin secretion. Accordingly, lack of endogenous IL-1β signaling in mice during refeeding and obesity diminished the concentration of insulin in plasma. IL-1β and insulin increased the uptake of glucose into macrophages, and insulin reinforced a pro-inflammatory pattern via the insulin receptor, glucose metabolism, production of reactive oxygen species, and secretion of IL-1β mediated by the NLRP3 inflammasome. Postprandial inflammation might be limited by normalization of glycemia, since it was prevented by inhibition of the sodium-glucose cotransporter SGLT2. Our findings identify a physiological role for IL-1β and insulin in the regulation of both metabolism and immunity.
- 16 January 2017
- Published by Springer Nature in Nature Immunology
- Vol. 18 (3) , 283-292
Top Cited PapersPostprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation
The deleterious effect of chronic activation of the IL-1β system on type 2 diabetes and other metabolic diseases is well documented. However, a possible physiological role for IL-1β in glucose metabolism has remained unexplored. Here we found that feeding induced a physiological increase in the number of peritoneal macrophages that secreted IL-1β, in a glucose-dependent manner. Subsequently, IL-1β contributed to the postprandial stimulation of insulin secretion. Accordingly, lack of endogenous IL-1β signaling in mice during refeeding and obesity diminished the concentration of insulin in plasma. IL-1β and insulin increased the uptake of glucose into macrophages, and insulin reinforced a pro-inflammatory pattern via the insulin receptor, glucose metabolism, production of reactive oxygen species, and secretion of IL-1β mediated by the NLRP3 inflammasome. Postprandial inflammation might be limited by normalization of glycemia, since it was prevented by inhibition of the sodium-glucose cotransporter SGLT2. Our findings identify a physiological role for IL-1β and insulin in the regulation of both metabolism and immunity.
- 1 July 2016
- Published by Elsevier in Gastroenterology
- Vol. 151 (1) , 165-179
Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells
- 1 July 2016
- Published by Elsevier in Gastroenterology
- Vol. 151 (1) , 165-179
Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Glucose-dependent insulinotropic peptide (GIP) stimulates Glucagon-like peptide (GLP)-1 from human and mouse pancreatic islets partly via alpha-cell-derived IL-6
Introduction: Glucose-dependent insulinotropic peptide (GIP) induces the cytokine interleukin (IL)-6 in adipocytes. IL-6 enhances insulin secretion from β-cells via L- and α-cell-derived GLP-1.Therefore we hypothesized that GIP regulates Glucagon-like peptide (GLP)-1 as well as glucose control via IL-6. Methods/Design: Basic research study on isolated human and mouse pancreatic islets and FACS-sorted human α-and β-cells that were treated with GIP in vitro. For in vivo studies, GIP effects on GLP-1 and insulin secretion as well as glucose homeostasis were evaluated in mouse models with pharmacologic and genetic ablation of IL-6. Results: GIP induced IL-6 in mouse and human pancreatic α-cells, leading to GLP-1 and insulin secretion in pancreatic islets. This effect was impaired in the absence of IL-6 and modulated by IL-1β which stimulated IL-6 but directly impaired GLP-1 production. Furthermore, inhibition of the sodium glucose transporter (SGLT)2 with dapagliflozin - enhanced GIP-induced GLP-1 release. In vivo, GIP increased plasma GLP-1 and insulin, and improved glucose tolerance, which was potentiated by lipopolysaccharide and strongly decreased in IL-6-deficient mice or in the presence of a blocking anti-IL-6 antibody. In diabetic mice, IL-1β and IL-6 were massively upregulated in isolated islets and GIP lost its effects on glycaemia control and GLP-1 induction. Conclusion: These data indicate that GIP induces GLP-1 and insulin via α-cell-derived IL-6, and that this effect is modulated by IL-1β and SGLT2 inhibtion. During diabetes, the prevailing inflammation may attenuate GIP effects. These findings further support the concept that the immune system plays an integral role in the regulation of metabolism in physiology and pathology.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Glucose-dependent insulinotropic peptide (GIP) stimulates Glucagon-like peptide (GLP)-1 from human and mouse pancreatic islets partly via alpha-cell-derived IL-6
Introduction: Glucose-dependent insulinotropic peptide (GIP) induces the cytokine interleukin (IL)-6 in adipocytes. IL-6 enhances insulin secretion from β-cells via L- and α-cell-derived GLP-1.Therefore we hypothesized that GIP regulates Glucagon-like peptide (GLP)-1 as well as glucose control via IL-6. Methods/Design: Basic research study on isolated human and mouse pancreatic islets and FACS-sorted human α-and β-cells that were treated with GIP in vitro. For in vivo studies, GIP effects on GLP-1 and insulin secretion as well as glucose homeostasis were evaluated in mouse models with pharmacologic and genetic ablation of IL-6. Results: GIP induced IL-6 in mouse and human pancreatic α-cells, leading to GLP-1 and insulin secretion in pancreatic islets. This effect was impaired in the absence of IL-6 and modulated by IL-1β which stimulated IL-6 but directly impaired GLP-1 production. Furthermore, inhibition of the sodium glucose transporter (SGLT)2 with dapagliflozin - enhanced GIP-induced GLP-1 release. In vivo, GIP increased plasma GLP-1 and insulin, and improved glucose tolerance, which was potentiated by lipopolysaccharide and strongly decreased in IL-6-deficient mice or in the presence of a blocking anti-IL-6 antibody. In diabetic mice, IL-1β and IL-6 were massively upregulated in isolated islets and GIP lost its effects on glycaemia control and GLP-1 induction. Conclusion: These data indicate that GIP induces GLP-1 and insulin via α-cell-derived IL-6, and that this effect is modulated by IL-1β and SGLT2 inhibtion. During diabetes, the prevailing inflammation may attenuate GIP effects. These findings further support the concept that the immune system plays an integral role in the regulation of metabolism in physiology and pathology.
- 28 October 2014
- Published by American Diabetes Association in Diabetes
- Vol. 64 (4) , 1273-1283
Angiotensin II Induces Interleukin-1β–Mediated Islet Inflammation and β-Cell Dysfunction Independently of Vasoconstrictive Effects
Pathological activation of the renin-angiotensin system (RAS) is associated with the metabolic syndrome, and the new onset of type 2 diabetes can be delayed by RAS inhibition. In animal models of type 2 diabetes, inhibition of the RAS improves insulin secretion. However, the direct effects of angiotensin II on islet function and underlying mechanisms independent of changes in blood pressure remain unclear. Here we show that exposure of human and mouse islets to angiotensin II induces interleukin (IL)-1–dependent expression of IL-6 and MCP-1, enhances β-cell apoptosis, and impairs mitochondrial function and insulin secretion. In vivo, mice fed a high-fat diet and treated with angiotensin II and the vasodilator hydralazine to prevent hypertension showed defective glucose-stimulated insulin secretion and deteriorated glucose tolerance. Application of an anti–IL-1β antibody reduced the deleterious effects of angiotensin II on islet inflammation, restored insulin secretion, and improved glycemia. We conclude that angiotensin II leads to islet dysfunction via induction of inflammation and independent of vasoconstriction. Our findings reveal a novel role for the RAS and an additional rationale for the treatment of type 2 diabetic patients with an IL-1β antagonist.
- 28 October 2014
- Published by American Diabetes Association in Diabetes
- Vol. 64 (4) , 1273-1283
Angiotensin II Induces Interleukin-1β–Mediated Islet Inflammation and β-Cell Dysfunction Independently of Vasoconstrictive Effects
Pathological activation of the renin-angiotensin system (RAS) is associated with the metabolic syndrome, and the new onset of type 2 diabetes can be delayed by RAS inhibition. In animal models of type 2 diabetes, inhibition of the RAS improves insulin secretion. However, the direct effects of angiotensin II on islet function and underlying mechanisms independent of changes in blood pressure remain unclear. Here we show that exposure of human and mouse islets to angiotensin II induces interleukin (IL)-1–dependent expression of IL-6 and MCP-1, enhances β-cell apoptosis, and impairs mitochondrial function and insulin secretion. In vivo, mice fed a high-fat diet and treated with angiotensin II and the vasodilator hydralazine to prevent hypertension showed defective glucose-stimulated insulin secretion and deteriorated glucose tolerance. Application of an anti–IL-1β antibody reduced the deleterious effects of angiotensin II on islet inflammation, restored insulin secretion, and improved glycemia. We conclude that angiotensin II leads to islet dysfunction via induction of inflammation and independent of vasoconstriction. Our findings reveal a novel role for the RAS and an additional rationale for the treatment of type 2 diabetic patients with an IL-1β antagonist.